GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Alere Inc (NYSE:ALRPRB.PFD) » Definitions » Beta

Alere (ALRPRB.PFD) Beta : N/A (As of Dec. 15, 2024)


View and export this data going back to 2008. Start your Free Trial

What is Alere Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2024-12-15), Alere's Beta is Not available.


Alere Beta Historical Data

The historical data trend for Alere's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alere Beta Chart

Alere Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Alere Quarterly Data
Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Alere's Beta

For the Diagnostics & Research subindustry, Alere's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alere's Beta Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Alere's Beta distribution charts can be found below:

* The bar in red indicates where Alere's Beta falls into.



Alere Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.


Alere  (NYSE:ALRPRB.PFD) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Alere Beta Related Terms

Thank you for viewing the detailed overview of Alere's Beta provided by GuruFocus.com. Please click on the following links to see related term pages.


Alere Business Description

Traded in Other Exchanges
N/A
Address
Alere, Inc. develops rapid point-of-care diagnostic devices in cardiology, infectious disease, toxicology, diabetes, oncology, and women's health. North America accounts for the largest portion of the firm's revenue (55%), followed by Europe (19%), Asia-Pacific (14%), and the rest of the world (12%). Alere's headquarters are in Waltham, Massachusetts.
Executives
John Bridgen officer: Sr VP, Business Development 51 SAWYER ROAD, C/O INVERNESS MEDICAL INNOVATIONS INC, WALTHAM MA 02453
Geoffrey S Ginsburg director 51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
Renuka Uppaluri officer: Senior VP, Global R&D 51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
Mark Gladwell officer: Senior VP, Global Operations 51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
Gregg J Powers director C/O QUANTUM CORPORATION, 224 AIRPORT PARKWAY SUITE 300, SAN JOSE CA 95110
Jonathan Wygant officer: VP, Controller, CAO 3750 TORREY VIEW COURT, SAN DIEGO X1 92130
Thomas Mckillop director 51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
Melissa Guerdan officer: SVP, Global Quality & Reg. 51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
Daniella Cramp officer: Global Pres., Cardiometabolic 51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
Sanjay Malkani officer: Global Pres., Toxicology 51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
James Jr. Roosevelt director 51 SAWYER ROAD, SUITE 200, HOPKINTON MA 02453
Robert Bernard Hargadon officer: SVP, Global Human Resources 4327 LAKE WASHINGTON BLVD NE #6208, KIRKLAND WA 98033
John F Levy director C/O INNVERNESS MEDICAL INNOVATIONS, INC., 51 SAWYER ROAD, WALTHAM MA 02453
John Quelch director C/O INVERNESS MEDICAL INNOVATIONS INC, 51 SAWYER RD, WALTHAM MA 02453
Carol R Goldberg director C/O INVERNESS MEDICAL INNOVATIONS INC, 51 SAWYERS RD, WALTHAM MA 02453

Alere Headlines

From GuruFocus

Alere Inc.: Foreign Currency Translations and the Euro

By Carmine Romano Carmine Romano 12-21-2011

Prem Watsa Trims IBM, Berkshire Hathaway

By Tiziano Frateschi Tiziano Frateschi 02-26-2018

Shareholders Approve Alere, Abbott Merger

By Alberto Abaterusso Alberto Abaterusso 07-10-2017

Alere Reports 2nd Quarter

By Alberto Abaterusso Alberto Abaterusso 08-04-2017

Mario Gabelli's Asset Fund Q3 2014 Commentary

By Vera Yuan Vera Yuan 11-21-2014

3 Investors Sitting on Huge Cash Stockpiles

By Holly LaFon Holly LaFon 11-21-2017

Alere Reaches Settlement With SEC

By Alberto Abaterusso Alberto Abaterusso 09-29-2017

Diamond Hill Capital Comments on Alere Inc

By Vera Yuan Vera Yuan 03-17-2015

Watsa Buys 19 Holdings in What He Calls 'Stock-Picker's Market'

By Holly LaFon Holly LaFon 11-14-2017